PTO/SB/08A (10-96)

Date

Please type a plus sign (+) inside this box → 🗵 Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

ation unless it contains a valid OMB control number.

JUN 1 7 2004

Patent and Trademark Office: U.S. DEPAK INTERN 101 Department of a collection of Under the Paperwork Reduction Act of 1995, no persons are required to respond a collection of Under the Paperwork Reduction Act of 1995, no persons are required to respond a collection of Complete if Known Application Number 10/759,037 Substitute for form 1449A/PTO Filing Date 01/20/2004 INFORMATION DISCLOSURE First Named Inventor Shaul STATEMENT BY APPLICANT Group Art Unit 1648 Examiner Name (use as many sheets as necessary) Attorney Docket Number 27169 Of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scrial symposium, catalog, etc.) date, page(s), volume-issue number(s), T2 Cite Examiner No.1 publisher, city and/or country where published. Initial Davis, CG, "The many faces of epidermal growth factor repeats", New Biol. 1990 May;2(5):410-9. DeMeyer et al, "Organ and Species Specificity of Hepatitus B Virus (HBV) Infection: A Review of Literature with a Special Reference to Preferential Attachment of HBV to Human Hepatocytes", J. Viral Hepatitus, 4:145-153, 2997 Doolittlr et al, "Computer-based characterization of epidermal growth factor precursor", Nature. 1984 Feb 9-15;307(5951):558-60. Lecka-Czernik et al, "An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis", Mol Cell Biol. 1995 Jan; 15(1):120-8.

Neurath et al, "Hepatitis B virus contains pre-S gene-encoded domains", Nature.

Shouval et al, "Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines", Vaccine. 1994 Nov;12(15):1453-9.

inhibitory effect of anti-HBs and anti-preS1(21-47)", Virology. 1991

Neurath et al, "Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing", Vaccine. 1986 Mar;4(1):35-7. Petit et al, "HepG2 cell binding activities of different hepatitis B virus isolates:

1985 May 9-15;315(6015):154-6.

Feb; 180(2):483-91.

Examiner Considered Signature \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.